HOME >> BIOLOGY >> NEWS
New strategy for treating allergic disorders

Ghent − Oral intake of allergens or auto-antigens via the lactic acid bacterium Lactococcus lactis might be a new strategy for treating various kinds of auto-immune and allergic disorders. VIB researchers associated with Ghent University, in collaboration with the Academic Medical Center (AMC) in Amsterdam, have shown that auto-antigens or allergens can be administered orally via the lactic acid bacterium. Based on this principle, which has been patented by VIB, ActoGeniX − a spin-off from VIB and Ghent University − is already developing a variety of biopharmaceutical medicines for a range of clinical indications.

The immune system

Every day our immune system combats harmful substances and micro-organisms that seek to penetrate our body. However, if our immune system is not working properly, we are subject to a variety of diseases. In the case of auto-immune diseases, the immune system no longer distinguishes between our bodys own substances and foreign substances and begins to attack our own tissues and organs. In other cases, the immune system responds mistakenly to harmless substances, such as the house dust mite, milk products, or pollen. This inappropriate immune system reaction to contact with such substances (allergens) is called an allergy. Today, 20% of the European population suffers from an allergy, which is twice as many sufferers compared to 15 years ago.

Lactococcus as supplier of remedies

In its natural form, the lactic acid bacterium (Lactococcus lactis) is a well-known food bacterium that has been used since time immemorial to convert milk into cheese and yoghurt. In the battle against chronic intestinal diseases, VIB researchers have been using L. lactis as a producer of a drug against gastroenteritis. The initial results of the clinical trials are promising.

Now, the bacterium is also being used to fight other disorders. There are a number of active substances for the treat
'"/>

Contact: Ann Van Gysel
ann.vangysel@vib.be
329-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
1-Aug-2007


Page: 1 2

Related biology news :

1. Does EPA have an adequate strategy to oversee nanotechnologies?
2. High blood pressure medication strategy proves effective in Hispanic women
3. Rutgers: GM/GMO/Biotech crop containment strategy
4. Scientists identify new strategy for preventing acute and chronic brain disease
5. International risk research strategy and funding needed for nanotech safety
6. Study shows metabolic strategy of stressed cell
7. Trojan horse strategy defeats drug-resistant bacteria
8. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
9. Drug strategy makes cancer genes get lost in translation
10. Researchers develop new strategy for the treatment of CML
11. Nanotech safety needs specific government risk research strategy and funding

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/27/2020)... ... January 27, 2020 , ... Cytonus Therapeutics Inc. today announced ... entrepreneur, and former senior management consultant at McKinsey & Company who holds three ... investment firm. , “Chris Thorne has exceptional business acumen with a proven ...
(Date:1/23/2020)... ... January 23, 2020 , ... GIOSTAR/HEAMGEN ... from stem cells. The red blood cells are made utilizing a bioreactor ... for transfusion therapy and replaces the need for a human blood donor. ...
(Date:1/22/2020)... (PRWEB) , ... January 21, 2020 , ... Lifecycle Biotechnologies announces the new ... to each users’ unique needs based on their process requirements and accurately weighed to 0.001 ... Buffers , Salts , Sugars , Carbohydrates , ...
Breaking Biology News(10 mins):
(Date:1/27/2020)... ... January 27, 2020 , ... ... secured financing from strategic investors led by Halma plc , a FTSE ... Sonion, TDF Ventures, GII LLC, and WSJ Joshua Fund. A representative from Halma ...
(Date:1/24/2020)... ... January 24, 2020 , ... Sierra Instruments, global leader ... and controllers ideal for BioPharm OEMS. Sierra also announces RedyCompact™ ... thermal instruments employ high-precision MEMS (Micro-Electro Mechanical Systems) technology utilizing an advanced, ultra-stable ...
(Date:1/22/2020)... ... January 21, 2020 , ... Microbial Discovery Group LLC (MDG) ... Industrial and Institutional (I&I) Account Manager. Darrell will focus on servicing MDG’s partners ... over 30 years of sales experience working across multiple different market sectors such ...
(Date:1/10/2020)... ... January 09, 2020 , ... A new report from ... vendor qualification process, a critical element of clinical trial set up and execution. ... vendor qualification process creates delays in initiation in 7% of clinical trials for ...
Breaking Biology Technology:
Cached News: